Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries.

However, for the adjusted adalimumab sales volume, we observed a marginally significant increase in the countries where adalimumab biosimilars were available, compared to those where adalimumab biosimilars were not available for 12 HIEs (1.0 SU per 1000 population; p = 0.06).

also in 26,082 other papers